%0 Journal Article %A Hamish Gibbs %A Naomi R Waterlow %A James Cheshire %A Leon Danon %A Yang Liu %A Chris Grundy %A Adam J. Kucharski %A LSHTM CMMID COVID-19 Working Group %A Rosalind M. Eggo %T Population disruption: estimating changes in population distribution of the UK during the COVID-19 pandemic %D 2022 %R 10.1101/2021.06.22.21259336 %J medRxiv %P 2021.06.22.21259336 %X Mobility data have demonstrated major changes in human movement patterns in response to COVID-19 and associated interventions in many countries. This can involve sub-national redistribution, short-term relocations as well as international migration. In this paper, we combine detailed location data from Facebook measuring the location of approximately 6 million daily active Facebook users in 5km2 tiles in the UK with census-derived population estimates to measure population mobility and redistribution. We provide time-varying population estimates and assess spatial population changes with respect to population density and four key reference dates in 2020 (First lockdown, End of term, Beginning of term, Christmas). We also show how population estimates derived from the distribution of Facebook users vary compared to mid-2020 small area population estimates by the UK national statistics agencies. We estimate that between March 2020 and March 2021, the total population of the UK declined and we identify important spatial variations in this population change, showing that low-density areas have experienced lower population decreases than urban areas. We estimate that, for the top 10% highest population tiles, the population has decreased by 6.6%. Further, we provide evidence that geographic redistributions of population within the UK coincide with dates of non-pharmaceutical interventions including lockdowns and movement restrictions, as well as seasonal patterns of migration around holiday dates. The methods used in this study reveal significant changes in population distribution at high spatial and temporal resolutions that have not previously been quantified by available demographic surveys in the UK. We found early indicators of potential longer-term changes in the population distribution of the UK although it is not clear if these changes may persist after the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. This research was partly funded by the Bill & Melinda Gates Foundation (INV-003174: YL). EDCTP2 (RIA2020EF-2983-CSIGN: HPG). ESRC UBEL DTP (ES/P000592/1: HPG). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: YL). HDR UK (MR/S003975/1: RME). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (16/137/109: YL; NIHR200908: AJK, RME). UK DHSC/UK Aid/NIHR (PR-OD-1017-20001: HPG). UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: RME, YL). Wellcome Trust (206250/Z/17/Z: AJK). UK MRC (MC_PC_19067, MR/V038613/1: LD), UK EPSRC (EP/V051555/1: LD), The Alan Turing Institute under the EPSRC (EP/N510129/1: LD). UKRI Retail Business Datasafe (ES/L011840/1: JC). The following funding sources are acknowledged as providing funding for the working group authors. This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ; INV-016832: SRP; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1139859: BJQ; OPP1191821: KO'R). BMGF (INV-016832; OPP1157270: KA). CADDE MR/S0195/1 & FAPESP 18/14389-0 (PM). ERC Starting Grant (#757699: MQ). ERC (SG 757688: CJVA, KEA). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: AG, KLM, KP, MJ, RCB, WJE). FCDO/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: CIJ). HPRU (This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care200908: NIB). MRC (MR/N013638/1: EF; MR/V027956/1: WW). Nakajima Foundation (AE). NIHR (16/136/46: BJQ; 16/137/109: BJQ, FYS, MJ; 1R01AI141534-01A1: DH; NIHR200908: LACC; NIHR200929: CVM, FGS, MJ, NGD; PR-OD-1017-20002: AR, WJE). Royal Society (Dorothy Hodgkin Fellowship: RL). Singapore Ministry of Health (RP). UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: NGD, SC, WJE; MR/P014658/1: GMK). UKRI (MR/V028456/1: YJ). Wellcome Trust (206250/Z/17/Z: TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JDM, JH, KS, SA, SFunk, SRM; 221303/Z/20/Z: MK). No funding (DCT, SH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the LSHTM Observational Research Ethics Committee (ref 16834-1).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe terms of use of data from the Facebook Data for Good program prohibit unauthorised distribution. Data is available from the Facebook Data for Good Partner Program by application. Data processing and analysis code is available from https://github.com/hamishgibbs/facebook_population_2020_2021. We have also aggregated our population estimates to 2019 Local Authority Districts, available from https://zenodo.org/record/5013620. https://github.com/hamishgibbs/facebook_population_2020_2021 https://zenodo.org/record/5013620 %U https://www.medrxiv.org/content/medrxiv/early/2022/08/12/2021.06.22.21259336.full.pdf